The Division of Molecular Medicine and Gene Therapy is located at the Biomedical Center (BMC), Lund University, Sweden. Established as a joint venture between the Medical Faculty at Lund University and the Hematology Clinic at Lund University Hospital, our mission is to translate basic science to clinical applications.
Our research focuses on hematopoiesis, the continuous and dynamic process of blood cell formation. The laboratory consists of eight closely collaborating research groups that all share a common interest in investigating the properties of blood stem cells to eventually understand and treat hematological disorders.
Five of our researchers belong to the Hemato-Linné Excellence Linnaeus Research Environment funded by The Swedish Research Council and Lund University. Several of the groups are engaged in StemTherapy, a Strategic Research Area for Stem Cells and Regenerative Medicine that is also supported by The Swedish Research Council.
Congratulations to Roger Rönn and co-authors from the Woods group on their newly published article in Stem Cells. In their study "Reactive Oxygen Species Impair the Function of cd90+ Hematopoietic Progenitors Generated from Human Pluripotent Stem Cells", Roger and his colleagues explored the impact of reactive oxygen species (ROS) on hematopoietic cells generated in vitro from Human Pluripotent Stem Cells (hPSCs). They demonstrated that the vast majority of newly generated hematopoietic cells have supraphysiological levels of intracellular ROS in a standard human pluripotent stem cell differentiation system, resulting in their functional impairment. These findings indicate that ROS regulation is required for generating functional hematopoietic progenitor cells in vitro.
Congratulations to all authors!
Congratulations to Johan Richter on his success in being selected to give a plenary presentation during the Presidential Symposium at the EHA Annual Congress in Copenhagen, June 9-12, 2016. An attentive audience of more than 4,000 followed his talk about results of the EURO-SKI study, a multicenter open label trial estimating the persistence of molecular remission in Chronic Myeloid Leukemia (CML) patients after stopping Tyrosine Kinase Inhibitors (TKI).
- We hope that the results from this study can form the basis for new treatment guidelines and help move the concept of stopping TKI-therapy in CML patients with a deep molecular response into standard clinical practice, says Johan Richter, Professor at the Division of Molecular Medicine and Gene Therapy and Senior Consultant in Hematology at Skåne University Hospital.
Congratulations to Sandra Capellera-Garcia et al. whose paper "Defining the Minimal Factors Required for Erythropoiesis through Direct Lineage Conversion" was published today in Cell Reports. In this study, Sandra and her colleagues identified the transcription factors Gata1, Tal1, Lmo2, and c-Myc as the minimal set of factors required for direct conversion of mouse and human fibroblasts into erythroid progenitors. These findings increase our understanding of erythroid lineage development and move researchers one step closer to establishing protocols for red blood cell production in vitro.